KLP Kapitalforvaltning AS Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

KLP Kapitalforvaltning AS acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 8,400 shares of the company’s stock, valued at approximately $450,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Asset Management L.P.



boosted its stake in shares of Janux Therapeutics by 190.2% in the third quarter. Point72 Asset Management L.

P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after buying an additional 259,445 shares during the period. Victory Capital Management Inc.

raised its holdings in Janux Therapeutics by 715.0% in the 4th quarter. Victory Capital Management Inc.

now owns 242,409 shares of the company’s stock valued at $12,979,000 after acquiring an additional 212,664 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in shares of Janux Therapeutics by 492.2% during the 4th quarter.

Skandinaviska Enskilda Banken AB publ now owns 205,167 shares of the company’s stock valued at $10,771,000 after acquiring an additional 170,520 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Janux Therapeutics by 202.

1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares in the last quarter.

Finally, Barclays PLC increased its position in shares of Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the period.

Institutional investors and hedge funds own 75.39% of the company’s stock. Janux Therapeutics Stock Down 4.

5 %NASDAQ JANX opened at $25.77 on Friday. The company has a market cap of $1.

52 billion, a price-to-earnings ratio of -22.03 and a beta of 3.23.

Janux Therapeutics, Inc. has a twelve month low of $24.30 and a twelve month high of $71.

71. The business’s fifty day moving average is $34.09 and its 200 day moving average is $45.

29. Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.

36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13.

Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their BetsIn other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.

86. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $3,473,658.31.

This trade represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the business’s stock in a transaction that occurred on Friday, March 7th.

The stock was bought at an average cost of $31.02 per share, for a total transaction of $3,418,590.12.

Following the completion of the purchase, the director now owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. This trade represents a 1.

10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 11,668 shares of company stock valued at $548,183 in the last ninety days.

29.40% of the stock is currently owned by insiders. Wall Street Analyst Weigh InJANX has been the topic of a number of analyst reports.

Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.

00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. Wedbush restated an “outperform” rating and set a $76.00 price objective (up from $75.

00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd.

Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company.

According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $92.44.

View Our Latest Stock Analysis on JANXJanux Therapeutics Profile (Free Report)Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.Featured StoriesFive stocks we like better than Janux TherapeuticsWhat is Short Interest? How to Use ItArcher Aviation’s Africa Deal Could Boost ACHR StockOverbought Stocks Explained: Should You Trade Them?Are Short Sellers Wrong About These 3 Semiconductor Stocks?What Are Dividend Challengers?Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report)..